Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study.

Ishikane M, Watanabe K, Tsukada K, Nozaki Y, Yanase M, Igari T, Masaki N, Kikuchi Y, Oka S, Gatanaga H.

PLoS One. 2014 Jun 19;9(6):e100517. doi: 10.1371/journal.pone.0100517. eCollection 2014.

2.

[Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].

Liu B, Cai WP, Hu FY, Xu M, Lan Y, Tang XP.

Zhonghua Gan Zang Bing Za Zhi. 2013 Nov;21(11):829-33. doi: 10.3760/cma.j.issn.1007-3418.2013.11.008. Chinese.

PMID:
24331692
3.

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.

Domagalski K, Pawłowska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):745-54. doi: 10.1007/s10096-012-1799-z. Epub 2013 Jan 13.

4.

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR.

Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.

5.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

6.

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.

Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y, Kumada H.

J Gastroenterol. 2012 May;47(5):596-605. doi: 10.1007/s00535-012-0531-1. Epub 2012 Mar 23.

PMID:
22438096
7.

Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.

Riva E, Scagnolari C, Monteleone K, Selvaggi C, Picardi A, Mazzarelli C, Pizzigallo E, Vincenzi B, Carducci A, Antonaci S, Giannelli G, Antonelli G.

J Viral Hepat. 2012 Sep;19(9):650-3. doi: 10.1111/j.1365-2893.2012.01606.x. Epub 2012 Apr 1.

PMID:
22863269
8.

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A.

J Antimicrob Chemother. 2012 Jan;67(1):202-5. doi: 10.1093/jac/dkr439. Epub 2011 Oct 11.

9.

Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.

Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A.

Mol Med Rep. 2012 Feb;5(2):525-8. doi: 10.3892/mmr.2011.655. Epub 2011 Nov 1.

PMID:
22052088
10.

Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype.

Neukam K, Nattermann J, Rallón N, Rivero A, Caruz A, Macías J, Vogel M, Benito J, Camacho A, Mira J, Schwarze-Zander C, Barreiro P, Martínez A, Rockstroh J, Soriano V, Pineda J.

HIV Med. 2011 Sep;12(8):487-93. doi: 10.1111/j.1468-1293.2011.00912.x. Epub 2011 Mar 6.

11.

Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.

Arends JE, van Assen S, Stek CJ, Wensing AM, Fransen JH, Schellens IM, Spijkers SN, Mudrikova T, van Baarle D, Sprenger HG, Hoepelman AI.

Antivir Ther. 2011;16(7):979-88. doi: 10.3851/IMP1843.

PMID:
22024513
12.

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4.

Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, Kozielewicz D, Dybowska D.

Hepat Mon. 2013 Nov 25;13(11):e13678. doi: 10.5812/hepatmon.13678. eCollection 2013.

13.

Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.

Kamal SM, Kassim SK, Ahmed AI, Mahmoud S, Bahnasy KA, Hafez TA, Aziz IA, Fathelbab IF, Mansour HM.

Am J Gastroenterol. 2014 Feb;109(2):199-211. doi: 10.1038/ajg.2013.427. Epub 2014 Jan 21.

PMID:
24445571
14.

Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients.

Laguno M, Martínez-Rebollar M, Perez I, Costa J, Larrousse M, Calvo M, Loncá M, Muñoz A, González-Cordón A, Blanco JL, Martínez E, Gatell JM, Mallolas J.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1294-300. Epub 2012 Apr 20.

PMID:
22428909
15.

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA.

J Infect. 2013 Jul;67(1):59-64. doi: 10.1016/j.jinf.2013.03.010. Epub 2013 Mar 28.

PMID:
23542783
16.

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O.

Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.

PMID:
21374656
17.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.

J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.

PMID:
22173157
18.

Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients.

Nevot M, Boesecke C, Parera M, Andrés C, Franco S, Revollo B, Ingiliz P, Tural C, Clotet B, Rockstroh JK, Martinez MA; NEAT study group.

J Viral Hepat. 2014 Jun;21(6):e19-28. doi: 10.1111/jvh.12254. Epub 2014 Mar 27.

PMID:
24674023
19.

Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.

Lyoo K, Song MJ, Hur W, Choi JE, Hong SW, Kim CW, Bae SH, Choi JY, Choi SW, Shin EC, Yoon SK.

J Clin Virol. 2011 Dec;52(4):363-6. doi: 10.1016/j.jcv.2011.08.006. Epub 2011 Sep 9.

PMID:
21907615
20.

The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.

Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-dweik N, Yakoob R, Pasic F, Almohanadi M, Alejji K, Abdelmola A, Butt M.

Virology. 2013 Sep;444(1-2):292-300. doi: 10.1016/j.virol.2013.06.025. Epub 2013 Jul 16.

Items per page

Supplemental Content

Write to the Help Desk